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Acute increase in plasma osmolality as a cause of hyperkalemia in
patients with renal failure. These studies were performed in patients
with chronic renal failure to understand the mechanism(s) of hyperkale-
mia secondary to hypertonic NaCl infusion. In 10 patients, after
intravenous infusion of either 5% or 2.5% NaCl (6 mEq per kg body wt
for 120 minutes in both solutions), the maximum increase in plasma
potassium averaged 0.6 (range 0.3 to 1.3) mmol/liter (P < 0.01) or 0.3
(range 0.2 to 0.6) mmol/liter (P < 0.01), respectively. The rise of both
plasma potassium and osmolality was significantly higher during 5%
NaC1 than during 2.5% NaCI infusion (P < 0.01). A significant linear
correlation (P < 0.01) between plasma potassium and osmolality was
observed. Urinary potassium excretion was increased to a similar
extent by 5% NaCI and 2.5% NaCI infusion. The observed hyperkale-
mia, secondary to NaCI infusion, was independent of venous pH,
plasma bicarbonate, anion gap, insulin levels, and urinary norepineph-
rine and epinephrine excretion, and was associated with a fall in plasma
aldosterone concentration. In separate studies, nine patients were
treated with desoxycorticosterone acetate (DOCA; 20 mg i.m. for three
days) before receiving saline (5%) infusion. DOCA did not prevent the
level increase in plasma potassium that remained significantly corre-
lated with plasma osmolality (P < 0.01). In conclusion, hypertonic
NaCI infusion in patients with renal failure causes a clinically relevant
hyperkalemia despite increased renal excretion of potassium. This
hyperkalemia is independent of acid-base or hormonal mechanisms
known to regulate extrarenal homeostasis of potassium, and is strictly
correlated with a rise in plasma osmolality.
Experimental studies in dogs have shown that i.v. infusion of
hypertonic NaC1 or mannitol induces hyperkalemia [1—4]. Dilu-
tional acidosis has been proposed as a possible explanation for
such a phenomenon [5, 61. Maintenance of steady acid-base
balance, however, does not prevent the hyperkalemia [2, 4].
The lack of conclusive explanation may reflect incomplete
knowledge on the hormones regulating potassium homeostasis
and the possible relationship between changes in plasma potas-
sium and osmolality.
In healthy humans, this phenomenon was described only by
Moreno, Murphy and Goldsmith [7], who failed to provide any
explanation, since neither the relationship between plasma
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potassium and osmolality nor blood pH and the hormones
regulating potassium homeostasis, nor the external balance of
potassium were investigated. More recently, hyperkalemia was
observed in insulin deficient patients, both during administra-
tion of hypertonic glucose and endogenous hyperglycemia
[8—10]. In these patients, the hyperkalemia observed in coinci-
dence with increased plasma osmolality was prevented by
pharmacological doses of insulin, suggesting a role for insulin
deficiency. This mechanism, of course, cannot be considered in
healthy subjects, in whom a hypertonic glucose load induces a
fall in plasma potassium by stimulating endogenous insulin
release.
The role of plasma hyperosmolality per se on plasma potas-
sium levels, although poorly defined, is of obvious clinical
relevance. Particularly, in patients with renal insufficiency, in
whom the renal compensatory mechanisms are inadequate to
excrete potassium loads [11], the administration of hypertonic
NaC1 to treat hyponatremia, marked extracellular fluid volume
depletion [12] or, as elsewhere suggested [13, 14], to counteract
the electrocardiographic effects of hyperkalemia, could be even
dangerous.
On the basis of these observations, our aim was to evaluate:
first, the clinical relevance of hyperkalemia, evoked by hyper-
tonic NaCl infusion, in patients with chronic renal failure at risk
for this complication; second, the role of acid-base and hor-
monal changes, regulating the extrarenal plasma potassium
homeostasis; third, the tonicity of NaCI infusions as a cause of
hyperkalemia, independently of their possible effects on extra-
cellular fluid volume alterations.
Methods
Patients
Fifteen patients (13 males and 2 females, 18 to 59 years old)
with chronic renal failure and steady renal function in the last
months (creatinine clearance 10 to 40 mllmin), regularly fol-
lowed up as outpatients, gave informed consent and entered
this study. Each patient served as his own control. The diag-
nosis of primary renal disease (8 glomerulonephritis, 3 pyelo-
nephritis, 2 polycystic kidney disease, 2 nephrosclerosis) was
established by anamnestic, clinical, laboratory, radiological
data and, when indicated, by renal biopsy. No patient had
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diabetes mellitus, peripheral edema, congestive heart failure,
serum albumin less than 3 g/dl, salt-losing nephropathy, urinary
tract infection, clinical signs of extracellular volume depletion,
plasma potassium alterations (that is, kalemia greater than 5.0
mmoilliter), arterial blood pressure greater than 160 (systolic) or
100 mm Hg (diastolic).
Stabilization period
All patients were hospitalized and received a constant intake
of sodium (100 mmol/day) and potassium (40 mmollday) during
the study. All medications were withdrawn at least two weeks
before the study. No patient had significant urinary residual
volume as assessed by voiding cystography or echography; this
permitted complete collection of urine by spontaneous voiding.
In all patients, clearance studies were preceded by a stabiliza-
tion period during which urine collections and morning blood
samples were daily obtained for measurements of sodium,
potassium and creatinine. The stabilization was considered
satisfactory when the magnitude of changes in creatinine clear-
ance and 24-hour urine excretion of sodium and potassium did
not exceed 20% in three consecutive days. Experiments were
performed in the morning with patients in the recumbent
position. For safety's sake, the infusion of hypertonic NaC1
solution was interrupted whenever blood pressure (recorded
every 10 mm) exceeded 165 (systolic) or 105 (diastolic) mm Hg,
or whenever plasma potassium concentration (measured every
30 mm) exceeded 6.5 mEq/Iiter.
Clearance studies
Study 1: Relation of hypertonic NaG/-dependent hyperkale-
mia with plasma osmolality, acid-base balance, insulin and
catecholamines. These studies were performed in ten patients.
The primary renal diseases of these patients (9 males and 1
female, 21 to 59 years old) were glomerulonephntis in six,
pyelonephritis in two, polycystic kidney disease in one and
nephrosclerosis in one.
All experiments started at 8 a.m. after an overnight fast and
consisted of a control period followed by constant infusion of 6
mEq NaClJkg body wt over 120 minutes, randomly adminis-
tered either as 5% or 2.5% NaCl solution. Three consecutive
60-minute clearance studies were performed before hypertonic
saline infusion and six consecutive 30-minute clearance studies
were performed starting with saline infusion. Urine was col-
lected by spontaneous voiding. Blood samples were also col-
lected alter the end of the clearance studies (210, 240 and 360
mm after the starting of saline infusion). Plasma potassium,
sodium, chloride, creatinine, glucose and osmolality were mea-
sured in samples collected in basal and experimental condi-
tions. Blood volume, venous pH, plasma bicarbonate, plasma
renin activity, aldosterone and insulin were measured at the end
of the control period, at the end of the saline infusion and one
hour after withdrawal of saline infusion. Potassium, sodium,
chloride, creatinine and catecholamines (norepinephrine and
epinephrine) were measured in the urinary samples. Blood
pressure and pulse rate were measured every 10 minutes.
Study 2: Relation of hypertonic NaCI-dependent hyperkale-
mia with mineralocorticoid activity. These studies were per-
formed in nine patients. The primary renal diseases of these
patients (8 males and 1 female, 18 to 59 years old) were
glomerulonephritis in six, pyelonephritis in one, polycystic
kidney disease in one, nephrosclerosis in one.
Since plasma aldosterone fell during saline infusion (results of
study 1), the effects of hypertonic (5%) NaCI infusion, per-
formed as in study 1, were examined in nine patients after the
administration of desoxycorticosterone acetate (DOCA) for a
period of three consecutive days at the dosage of 20 mg
i.m./day.
Control consisted of the same subjects in which the effects of
hypertonic NaCI per Se, that is, without DOCA administration,
were studied. Assignment to DOCA or control study as the first
study was randomized.
Analytical determinations
Blood was obtained through an indwelling catheter located in
an antecubital vein of the arm not used for the infusion. Blood
volume (BV) was measured by Blue Evans' method with the
following formula: BV = QIC x (11(1 — Ht/lOO) where Q is the
quantity of dye injected, and C is the concentration of dye in
plasma. Anion gap (AG) was measured with the formula: AG =
Nap — (HCO3p + CIp) where Nap, HCO3p and CIp are the
plasma concentrations of sodium, bicarbonate and chloride,
respectively.
Plasma potassium and sodium levels were measured with a
flame photometer (Beckman Instruments, mc, Fullerton, Cali-
fornia, USA). In both studies, plasma potassium and sodium
levels were measured in triplicate. The coefficients of variation
were 1.1% (0.1% SEM) for potassium and 0.7% (0.1% SEM) for
sodium in Study 1 and 1.0% (0.1% sEM) for potassium and 0.8%
(0.1% SEM) for sodium in Study 2. Plasma and urine osmolality
was measured with an osmometer (Model 250 D, Fiske Asso-
ciates, mc, Uxbridge, Massachusetts, USA). Chloride, glu-
cose, creatinine were measured with a Technicon autoanalyzer;
plasma renin activity, aldosterone and insulin by standard
radioimmunoassay. Catecholamines were determined fluoro-
metrically, as described in detail elsewhere [15], in urine
acidified with 37% HCI immediately after the collection and
stored at —30°C. Venous pH and partial pressure of carbon
dioxide were measured by a blood gas analyzer (Radiometer,
Copenhagen, Denmark) and plasma bicarbonate level was
calculated from the results of these measurements.
Statistics
All values are expressed as means SEM. Statistical calcu-
lations were performed by an IBM computer using the UCLA
BMDP program, revised in 1985. Analysis of variance [16] and
linear regression analysis were used. P values of 0.05 or less
were considered significant.
Results
Study I: Relation of hypertonic NaG/-dependent
hyperkalemia with plasma osmolality, acid-base, insulin and
catecholamines
After 5% NaC1 infusion, mean plasma potassium concentra-
tion increased progressively. The maximum rise averaged 0.6
(0.09 SEM) mmol/liter (range 0.3 to 1.3; peak level of plasma
potassium 6.2; Fig. 1). The simultaneous mean increase in
plasma osmolality (mean basal value was 294 3.0 SEM, peak
level of plasma osmolality during 5% NaCI infusion was 316
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Fig. 2. Effectof 5% (e—.—) and 2.5% (----) hypertonic NaCI infusion on
plasma osmolality. Each value represents the mean SEM of values in
ten subjects. The probability of the difference was 0.05 (0) and 0.01(00).
mOsm/kg H20) was 16.0 1.3 SEM mOsm/kg H20 at 180
minutes (60 mm after the end of NaC1 infusion; Fig. 2). At 360
mm (that is, 240 mm after the end of 5% NaC1 infusion) both
plasma potassium and osmolality returned to basal level (Figs.
1 and 2). After 2.5% NaCI infusion, the mean increase in plasma
potassium averaged 0.3 0.05 SEM mmol/liter (range 0.2 to 0.6;
peak level of plasma potassium 5.5; Fig. 1), plasma osmolality
(mean basal value was 294 2.8 SEM, peak level of plasma
osmolality during 2.5% NaCI was 308 mOsm/kg H20) rose by
9.2 mOsm/kg H20 at 180 minutes (Fig. 2). At 360 minutes both
plasma potassium and osmolality returned to basal level (Fig. 1
and 2). The increment of both plasma potassium and plasma
osmolality at 60, 90, 120, 150, 180 minutes was significantly
greater during 5% NaCl than during 2.5% NaCI (Fig. 1 and 2).
The relation between plasma osmolality and plasma potassium,
assessed by linear regression analysis, was significantly posi-
tive (P < 0.01) after the infusion of both 5% and 2.5% NaCI
(Fig. 3).
As shown in Table 1, the hypertonic infusion of both 5% and
2.5% NaCl increased urine output, urinary osmolar excretion
and urinary excretion of sodium and potassium without chang-
ing creatinine clearance. The changes in plasma potassium
concentration during the infusion of hypertonic NaCl did not
correlate with the levels of renal function, as assessed by
creatinine clearance (P > 0.1). Urinary potassium excretion
was similar in 5% and 2.5% NaCI studies. No significant
changes were observed in pH (range 7.27 1 to 7.359) and plasma
bicarbonate (range 11.2 to 22.9) after NaCI infusion (Table 2).
The anion gap (range 11.7 to 21.8) remained unchanged
throughout the study (Table 2). As expected, hypertonic saline
infusion induced a rise in blood volume and a fall in plasma
renin activity. Plasma aldosterone was decreased by saline
infusion, but remained within our normal range (70 to 250 pglml)
in all patients. No changes were observed in plasma concentra-
tions of glucose, insulin nor in urinary excretion of epinephrine
and norepinephrine both during and after hypertonic NaC1
infusion. Hypertonic saline infusion did not cause any signifi-
cant changes in mean arterial blood pressure and pulse rate, so
that it was not necessary to interrupt the infusion studies in any
patient.
Study 2: Relationship of hypertonic NaC1-dependent
hyperkalemia with mineralocorticoid activity
The changes in plasma potassium concentration after 5%
NaC1 infusion were not modified by pretreatment with DOCA
(Fig. 4); plasma potassium concentration, in fact, increased up
to 0.5 mmol/liter both without DOCA (at 180 mm) and with
DOCA (at 180 mm). As in Study 1, the relationship between
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Fig. 1. Effect of 5% (i—) and 2.5% (----) hypertonic NaG! infusion on
plasma potassium concentration. Each value represents the mean
SEM of values in ten subjects. The probability of the difference was 0.05
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Fig. 3. Correlation between plasma potassium and plasma osmolality
after 5% (0) and 2.5% (•) NaC! infusion in subjects with chronic renal
failure. Slope: 0.050; intercept: —10,994; r = 0.650, P < 0.0!.
30 60
304 Conte et a!: Increase in osmolality causes hyperkalemia
Table 1. Effects of hypertonic (2.5% and 5%) NaCl infusion on creatinine clearance, urine output, osmolal, sodium and potassium urinary
excretion
Creatinine
clearance
Urine
output
Osmolal
urinary
excretion
mOsm/min
Na urinary
excretion
K urinary
excretion
mi/mm mmoi/min
2.5% Sodium chloride
Basal 24.9 3.9 1.7 0.2 0.516 0.064 0.108 0.013 0.034 0.007
0—120 mm 25.0 4.1 2.8 0.5 0.868 0.137" 0.276 0.055" 0.045 o.007a
120—180 mm 24.6 4.0 3.3 0.5" 0.849 0.146" 0.316 0055b 0.060 0007b
5% Sodium chloride
Basal 23.6 4.2 1.4 0.1 0.446 0.041 0.084 0.017 0.030 0.003
0—120 mm 25.0 4.5 2.3 0.2" 0.729 0.062" 0.219 0031b 0.043 o.o04
120—180 mm 25.8 3.7 3.6 0.4" 1.094 0.109" 0.341 0.042" 0.061 0.008"
Values are means SEM.
P < 0.05
"P < 0,01
Table 2. Effects of hypertonic (2.5% and 5%) NaCI infusion on plasma potassium, plasma bicarbonate, anion gap, venous pH, plasma renin
activity and aldosterone, blood volume, plasma glucose, plasma insulin and urinary excretion of epinephrmne and norepinephrine
K HC03mmoi/liter AG pH
PRA
nglinl/hr
Aldosterone
pg/mi
Blood
Volume
ml
Glucose
gIdi
Insulin
sU/m1
E NE
tg/hr
2.5% Sodium
chloride
Basal 4.0
0.05
19.6
0.9
15.2
1.2
7.321
0.018
2.2
0.6
449
84
3538
93
0.95
0.09
20.0
4,2
0.21
0.06
3.91
1.32
0—20mm 4.2"
0.04
19.4
0.9
15.3
1.1
7.290
0.016
1.sa
0.5
282b
36
4460b
295
0.99
0.11
21.2
4.1
0.17
0.04
3.83
1,22
120—180mm 4.3"
0.03
19.1
1,0
15.0
1,3
7.290
0.014
1.3"
0.3
297b
41
4324b
216
0.92
0.13
20.1
4.0
0.25
0.14
3.91
1.19
Sodium
chloride
Basal 4.1
0.05
20.0
0.9
15.1
2.0
7.336
0.017
1.4
0.3
345
79
3568
188
0.93
0.12
18.6
3.8
0.23
0,07
3.40
1.01
0—120 mm 4.5"
0.05
19.8
0.8
15.5
2.0
7.321
0.015
Ø,9
0,2
226
43
4437"
354
0.97
0.14
20.4
4.1
0.27
0.09
3.22
1.28
120—180 mm 4.7"
0.04
19.0
0.8
15.4
2.2
7.324
0.015
0.7"
0.1
216b
39
4384b
249
0.91
0.12
20.9
3.7
0.28
0.09
3.67
1.15
Abbreviations are: AG, anion gap; PRA, plasma renin activity; E, epinephrine; NE, norepinephrine. Values are means SEM.
a p < 0.05
b < 0.01
plasma osmolality and plasma potassium, assessed by linear
regression analysis, was significantly positive (P < 0.01) after
infusion of 5% NaCl with or without DOCA (Slope: 0.092;
intercept: —23.961; r = 0.669).
As shown in Table 3, the infusion of hypertonic NaC1 with or
without DOCA induced a similar increase in urine output, in
urinary osmolar excretion and in urinary excretion of sodium
and potassium. The changes in plasma potassium concentration
during hypertonic saline infusion with or without DOCA did not
correlate with the levels of renal function, as assessed by
creatinine clearance (P > 0.1). No changes were caused by
DOCA in venous pH (range 7.276 to 7.359), plasma bicarbonate
(range 11.3 to 22.6) and anion gap (range 11.5 to 21.5, Table 4).
Infusion of NaCl solution produced a rise in blood volume and
a fall in plasma renin activity and aldosterone (Table 4). No
changes were observed in plasma concentrations of glucose,
insulin nor in urinary excretion of epinephrine and norepineph-
rine after NaCl infusion with or without DOCA. Hypertonic
saline infusion produced no changes in mean arterial blood
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Fig. 4. Effect of hypertonic (5%) NaG! infusion without (I—H) and with
(----) DOCA pretreatment on plasma potassium. Each value represents
the mean SaM of values in nine subjects.
Conte et a!: Increase in osmolality causes hyperkalemia 305
Table 3. Effects of hypertonic 5% NaCI infusion without and with DOCA on creatinine clearance, urine output, osmolal, sodium and
potassium urinary excretion
Creatinine
clearance
Urine
output
Osmolar
urinary
excretion
mOsmimin
Na urinary
excretion
K urinary
excretion
mi/mm mmol/min
5% Sodium chloride
without DOCA
Basal 27.9 4.0 1.9 0.3 0.501 0.079 0.123 0.023 0.045 0.008
0—120 mm 26.8 5.6 3.0 0.3k 0.919 0.072a 0.296 0.026a 0.072 0.014a
120—180 mm 27.0 5.2 4.4 0.4a 1.197 O.O58 0.451 0.054a 0.084 0.009
5% Sodium chloride
with DOCA
Basal 28.6 5.0 1.4 0.2 0.777 0.148 0.093 0.015 0.032
0—120 mm 29.3 4.0 2.9 0.2a 1.135 0.236a 0.287 0.024a 0.097 0.035
120—180mm 29.8 4.4 3.8 0.2a 1.475 0.174 0.380 0.026 0.066 o.olIa
Values are means SaM.
ap <0.01
Table 4. Effects of hypertonic 5% NaCl infusion without and with DOCA on plasma potassium, plasma bicarbonate, anion gap, venous pH,
plasma renin activity and aldosterone, blood volume, plasma glucose, plasma insulin and urinary excretion of epinephrine and norepinephrine
Blood E NE
HCOj PRA Aldosterone Volume Glucose InsulinK mmo!/iiter AG pH ng/ml/hr pg/mi ml g/dl rsU/m! pg/hr
Sodium chloride
without DOCA
Basal 4.2 20.0 15.2 7.330 1.3 377 3601 1.01 19.5 0.36 3.21
0.05 0.8 1.9 0,016 0.2 70 143 0.08 3.4 0.08 0.90
120 mm 4.6a 19.5 15.4 7.321 0.7a 247 45l2 0.96 20.3 0.34 3.34
0.05 0.7 2.0 0.014 0.2 34 259 0.10 3.9 0.09 0.92
180 mm 4•7a 19.0 15.3 7.323 0.7a 258k 4502 0.99 21.0 0.39 2.85
0.05 0.6 1.9 0.014 0.2 36 218 0.11 4.1 0.06 0.84
Sodium chloride
with DOCA
Basal 4.1 20.1 15.0 7.314 1.6 351 3555 0.94 18.2 0.29 3.09
0.05 1.2 1.8 0.018 0.3 94 131 0.09 3.5 0.03 0.81
120 mm 45a 19.6 15.4 7.314 0.8a 267k 449I 0.90 19.6 0.35 2.78
0.06 1.1 1.9 0.019 0.2 67 225 0.10 3.4 0.07 0.79
180 mm 4.6a 20.5 15.1 7.330 0.7a 244 4482k 0.98 19.9 0.31 2.64
0.05 1.0 2.1 0.021 0.2 57 251 0.11 3.7 0.10 0.75
Abbreviations are: AG, anion gap; PRA, plasma renin activity; E, epinephrine; NE, norepinephrine. Values are means SEM.
ap< 0.01
pressure or pulse rate, so that it was not necessary to interrupt
the infusion studies in any patient.
Discussion
Previous studies, mainly in laboratory animals [1—5], have
demonstrated that infusion of hypertonic NaCI or mannitol is
associated with hyperkalemia due to extrarenal redistribution of
potassium. Nonetheless, the increased plasma osmolality, ex-
cept for the well-known clinical hyperkalemia associated with
hyperglycemia in insulin-deficient patients [8—10], is not usually
taken into account in clinical practice as a factor influencing the
plasma potassium homeostasis [14, 17, 18]. Our study shows
that the i.v. infusion of hypertonic NaCl causes a relevant rise
in plasma potassium concentration in normokalemic patients
with reduced renal function. Extreme caution should, there-
fore, be used in administering intravenously hypertonic NaC1
and the therapeutic recommendation to use hypertonic NaC1 for
counteracting the harmful effects of hyperkalemia [13, 14]
should be revised. Moreover, it is very important to note that
hyperkalemia observed both during study 1 and 2 was blunted
by the increased urinary excretion of potassium, due to in-
creased sodium delivery to distal sites of the nephron where
cationic (Na-K) exchange occurs [19]. This kaliuresis, how-
ever, is clearly insufficient to counterbalance the hyperkalemic
effect. These findings suggest that life-threatening hyperkalemia
may result when hypertonic NaCl is infused in uremic patients
with oligoanuna and/or when potassium-sparing diuretics and!
or supplements of potassium are administered.
Traditionally, four factors are thought to affect the relative
distribution of body potassium between intra- and extracellular
fluids: acid-base balance, mineralocorticoids, insulin and adren-
ergic activity [14]. Therefore, we have examined whether the
rise in plasma potassium caused by hypertonic NaCI adminis-
tration depends on any of these factors.
A decrease in blood pH is a well established cause of
hyperkalemia. In our patients with renal failure the infusion of
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hypertonic NaC1 did not significantly decrease blood pH. Re-
duction in plasma bicarbonate concentration may influence the
transcellular distribution of potassium, independently of any
associated change in blood pH [201. Changes in plasma bicar-
bonate concentration, however, was not observed in our stud-
ies. In theory, also changes in the anionic composition of the
plasma may play a role in the transcellular movement of
potassium but this hypothesis was ruled out by the unmodified
anion gap.
In our patients, hypertonic saline infusion caused a significant
fall in plasma aldosterone concentration, secondary to the
marked increase in blood volume. In hypoaldosteronism,
DOCA administration corrects hyperkalemia without any de-
tectable increase in urinary or fecal potassium excretion [211. In
our patients, however, pharmacological doses of DOCA did not
prevent or blunt the hyperkalemia induced by hypertonic
saline. This different effect of mineralocorticoids in our patients
as compared with patients with hyporeninemic hypoaldoster-
onism may be explained by the normal, rather than low, plasma
aldosterone levels observed after hypertonic saline. In other
words, treatment with DOCA may influence extracellular po-
tassium homeostasis only in subjects with pre-existing hypoal-
dosteronism.
Insulin contributes to the extrarenal defense against hyper-
kalemia by enhancing cellular uptake of potassium [221. Thus,
indeed, very high concentrations of potassium directly stimu-
late insulin release from the pancreas. Infusion of KCI which
substantially elevates plasma concentrations of potassium
(>1.5 mEq/liter) in dogs is in fact associated with significant
increases of plasma insulin levels [23]. Moreover, in the latter
study, plasma insulin concentration was not significantly en-
hanced when the plasma potassium concentrations increased
from about 4.0 to 5.3 mEq/liter. Furthermore, in another study
[24], in response to a small increase of mean plasma potassium
concentration (from 4.16 to 4.79 mEq/liter) induced by KCI
infusion, peripheral insulin levels remained unchanged. In our
patients, the maximum increments in plasma potassium, in-
duced by both 2.5% and 5% NaCI infusion, averaged 0.3 and 0.6
mEq/liter, respectively, and the maximum values of plasma
potassium averaged within the normal range, that is, 4.3 and 4.7
mEq/liter, respectively. In agreement with previous observa-
tions [23, 24], increases in mean plasma potassium levels within
the physiologic range did not lead to significant changes in
peripheral insulin levels in our patients.
The adrenergic nervous system is known to participate in the
regulation of potassium distribution in body fluids [25—271. It
has been observed, in fact, that infusions of epinephrine in low
doses blunt the increment in serum potassium induced by
intravenous KCI [25]. However, no significant changes in
plasma catecholamines were detected during KCI infusions that
increased the plasma potassium from 0.6 to 0.8 mEq/liter [25,
27]. In our patients, the increases in the mean plasma potassium
by 0.3 to 0.6 mEq/liter, induced by hypertonic NaCI infusions,
were even lower and were not associated with changes in
epinephrine and norepinephrine excretion rates. Urinary excre-
tion of catecholamines provides a better estimate of adrenergic
activity than plasma catecholamines levels, because of the very
short half life of these hormones [28]. Epinephrine and norepi-
nephrine may have counterbalancing effects on transcellular
potassium movement: epinephrine has beta2 effects which
would tend to promote potassium movement into cells, whereas
norepinephrine has alpha effects which may retard potassium
entry into cells. Theoretically, opposite changes in both epi-
nephrine and norepinephrine excretion rates, even if not signif-
icant per Se, may combine to modify the hyperkalemic response
to hypertonic saline infusion. Our results, however, do not
show directionally opposite alterations in these parameters at
the maximum increases in mean plasma potassium, that is 0.3
and 0.6 mEq/liter (Table 2). Therefore, a role of catecholamines
in promoting or blunting hyperkalemia is not apparent from our
study.
Our data clearly demonstrate that the NaCI-dependent rise in
plasma potassium occurs in tight conjunction with a significant
increase in plasma osmolality. This, in fact, is shown by the
positive linear correlations between changes in plasma potas-
sium and plasma osmolality after NaCl infusion with or without
DOCA pretreatment. As expected, urinary potassium and so-
dium excretions, as well as blood volume, were increased to a
similar extent by 5% NaCl and 2.5% NaC1. The load of NaCI
administered i.v. by 5% and 2.5% hypertonic solution was
identical and caused, therefore, similar changes in blood vol-
ume and as well as in urinary excretion of both sodium and
potassium (Table 1). The more pronounced increase in kalemia
during 5% than during 2.5% NaCl, despite similar urinary
excretion rates of potassium, indicates that an extrarenal os-
motic mechanism is responsible for the higher rise of potassium
after 5% NaCI. Taken together, these findings demonstrate that
the degree of hyperkalemia is associated with different degrees
of NaCI tonicity, independently of blood volume changes, and
strongly suggest that an osmotic mechanism accounts for the
shift of potassium from the cellular compartment.
The exact mechanism(s) shifting potassium out of the cells
after hypertonic saline infusion cannot be defined in a clinical
study. A solvent drag phenomenon moving K-rich intracellu-
lar water into the hypertonic extracellular compartment may be
suggested. An alternative explanation is that changes in tonicity
can alter cell metabolism of isolated tissue [29, 30] and that this
impairment of intracellular metabolism can affect the transcel-
lular potassium gradients: damaged cells exhibit a leak of
potassium at an accelerated rate [3 1—33].
In conclusion, this study shows that the hypertonic NaCI
infusion in uremic patients may cause a clinically relevant
hyperkalemia, in spite of increased renal excretion of potas-
sium. This phenomenon emphasizes the need for careful mon-
itoring of plasma potassium during acute elevations of plasma
osmolality, particularly in oligoanuric patients. The hyperkale-
mia is independent of changes in acid-base balance, anion gap
or hormones known to regulate extrarenal homeostasis of
potassium. This effect is strictly correlated with the rise in
plasma osmolality or with the different degree of NaCI tonicity,
independently of blood volume changes.
Reprint requests to Prof. Giuseppe Conte, M.D., Policlinico Mater-
domini, via Tommaso Campanella, 88100 Catanzaro, Italy.
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